PharmaCyte Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für PharmaCyte Biotech zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Mar 22

PharmaCyte Biotech says CEO to step down, announces strategic review of business

Oct 07

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Aug 15

Is This A Good Time To Invest In PharmaCyte?

Jan 07

PharmaCyte Biotech: Buy The 'Dump'

Aug 21

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da PharmaCyte Biotech jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:PMCB - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
7/31/2024	N/A	4	-3	-3	N/A
4/30/2024	N/A	-17	-2	-2	N/A
1/31/2024	N/A	-15	-2	-2	N/A
10/31/2023	N/A	-10	-2	-2	N/A
7/31/2023	N/A	-10	-2	-2	N/A
4/30/2023	N/A	-4	-4	-4	N/A
1/31/2023	N/A	-6	-5	-5	N/A
10/31/2022	N/A	-6	-4	-4	N/A
7/31/2022	N/A	-5	-4	-4	N/A
4/30/2022	N/A	-4	-4	-4	N/A
1/31/2022	N/A	-4	-4	-4	N/A
10/31/2021	N/A	-4	-4	-4	N/A
7/31/2021	N/A	-4	-4	-4	N/A
4/30/2021	N/A	-4	-3	-3	N/A
1/31/2021	N/A	-3	-3	-3	N/A
10/31/2020	N/A	-3	-3	-3	N/A
7/31/2020	N/A	-4	-2	-2	N/A
4/30/2020	N/A	-4	-2	-2	N/A
1/31/2020	N/A	-4	-2	-2	N/A
10/31/2019	N/A	-4	-3	-3	N/A
7/31/2019	N/A	-4	-3	-3	N/A
4/30/2019	N/A	-4	-3	-3	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-6	-4	-4	N/A
7/31/2018	N/A	-6	-5	-5	N/A
4/30/2018	N/A	-7	N/A	-5	N/A
1/31/2018	N/A	-7	N/A	-5	N/A
10/31/2017	N/A	-6	N/A	-4	N/A
7/31/2017	N/A	-5	N/A	-3	N/A
4/30/2017	N/A	-4	N/A	-3	N/A
1/31/2017	N/A	-4	N/A	-4	N/A
10/31/2016	N/A	-5	N/A	-4	N/A
7/31/2016	N/A	-6	N/A	-4	N/A
4/30/2016	N/A	-6	N/A	-4	N/A
1/31/2016	N/A	-8	N/A	-4	N/A
10/31/2015	N/A	-7	N/A	-4	N/A
7/31/2015	N/A	-10	N/A	-5	N/A
4/30/2015	N/A	-10	N/A	-5	N/A
1/31/2015	N/A	-24	N/A	-4	N/A
10/31/2014	N/A	-23	N/A	-4	N/A
7/31/2014	N/A	-24	N/A	-2	N/A
4/30/2014	N/A	-27	N/A	-2	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von PMCB über der Sparquote liegt (2.6%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von PMCB schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von PMCB in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von PMCB schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von PMCB schneller wachsen werden als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von PMCB in 3 Jahren voraussichtlich hoch sein wird

PharmaCyte Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

PharmaCyte Biotech, Inc. announced delayed annual 10-K filing

PharmaCyte Biotech, Inc., Annual General Meeting, Apr 29, 2024

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. Provides Corporate Update on Cell-In-A-Box Technology

PharmaCyte Biotech, Inc. announced delayed 10-Q filing

High number of new and inexperienced directors

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for 7,750,000 shares, for $25.19 million.

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Announces Resignation of Jack E. Stover as Director

PharmaCyte Biotech, Inc. Announces Resignation of Gerald W. Crabtree as Chief Scientific Officer

PharmaCyte Biotech, Inc., Annual General Meeting, Dec 28, 2022

PharmaCyte Biotech, Inc. Announces Management Changes

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech, Inc. Announces Board Appointments

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

Iroquois Capital Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech

PharmaCyte Biotech, Inc. Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. Reports Positive Interim Results in Malignant Ascites Mouse Model Study

Iroquois Capital Commences Consent Solicitation to Reconstitute Pharmacyte Biotech Board of Directors

Iroquois Capital Issues a Statement in Response to Pharmacyte Biotech

Iroquois Capital Delivers Open Letter to Pharmacyte Biotech Board of Directors

PharmaCyte Biotech, Inc., Annual General Meeting, Aug 25, 2022

PharmaCyte Biotech, Inc. (NasdaqCM:PMCB) announces an Equity Buyback for $10 million worth of its shares.

PharmaCyte Biotech, Inc. Initiates Studies to Confirm its Pancreatic Cancer Therapy Can Treat Malignant Ascites

Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech, Inc. Appoints Matthias Löhr to the Board

PharmaCyte Biotech Receives A Notification Letter from Regulation Department of the Nasdaq Stock Market

PharmaCyte Biotech, Inc. Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech, Inc Updates Status of Investigational New Drug Application to FDA

Is This A Good Time To Invest In PharmaCyte?

Pharmacyte Biotech, Inc. Study Proves Capsule Material Is Not Toxic for Encapsulated Cells

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech, Inc. Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study

PharmaCyte Biotech, Inc. Announces Encapsulation Material Does Not Alter Cellular DNA

Pharmacyte Biotech, Inc. Releases More Positive Results from U.S. Food and Drug Administration-Required Biocompatibility Tests

Pharmacyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise

PharmaCyte Biotech: Buy The 'Dump'

PharmaCyte Biotech Common Stock Deleted from Other OTC

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreatic Cancer Treatment

PharmaCyte Biotech, Inc. Announces Update on Study Progress

PharmaCyte Biotech, Inc. Announces Stability Test Results on Cells from Master Cell Bank

PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold

PharmaCyte Biotech Begins DNA Sequence and Stability Studies in Response to FDA Requests for Its Clinical Trial Product

PharmaCyte Biotech Begins Physical Testing of CypCaps in Response to FDA Recommendations for Its Clinical Trial Product

PharmaCyte Biotech, Inc. Successfully Completes 9-Month Stability Study

PharmaCyte Biotech, Inc. Receives U.S. FDA Clinical Hold Letter

PharmaCyte Biotech, Inc. Announces Dr. Gerald W. Crabtree Will No Longer Serve as Chief Operating Officer But Instead Will Serve as Chief Scientific Officer

U.S. FDA Places PharmaCyte Biotech, Inc.’s Investigational New Drug Application on Hold

PharmaCyte Biotech Continues to Engage the FDA During 30-Day Comment Period

PharmaCyte Biotech, Inc. Successfully Completes Six-Month Stability Study

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken